Disseminated on behalf of Supreme Critical Metals.

The company is Supreme Critical Metals, tickers 🇨🇦CRIT and 🇺🇸VRCFF, and it’s shaping up as a potentially under-the-radar play in the critical minerals space. Supreme is advancing its newly acquired Silver Vista Project in British Columbia, located just 23 km from the NAK discovery and 30 km from Amarc’s Duke deposit — one of the most active exploration corridors in the province.

A previous drill program delivered standout results, including 46 metres of 48 g/t silver and 0.62% copper, with peak grades hitting 431 g/t silver. The target here is a near-surface, open-pit silver-copper system, which can be drilled quickly and cost-effectively.

Supreme also announced another key acquisition recently — the Gold Springs 1 property in Nevada — while also completing a full site visit at Silver Vista and locking in targets for a potential upcoming drill program. With a tight share structure of just ~28M shares and both silver and copper classified as high-value critical metals, Supreme Critical Metals is emerging as one of the most overlooked early-stage stories in the sector right now.

Disclaimer: This newsletter was sponsored by Supreme Critical Metals, and was funded by Senergy Capital. We have been compensated for this newsletter. we only express my opinion based on my experience. Your experience may be different. This newsletter is for educational and inspirational purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. There is no guarantee of gains or losses on investments. Please do your own due diligence. we are not a financial advisors, and this is not a financial advice channel. All information is provided strictly for educational purposes. It does not take into account anybody's specific circumstances or situation. If you are making investment or other financial management decisions and require advice, please consult a suitably qualified licensed professional.

The S&P rallied 1.47% yesterday, the Nasdaq surged 2.6%, and major tech names ripped higher to start the week.

But here's what separates winning traders from the crowd:

→ While others panic-sell, we're scanning for oversold opportunities
→ While everyone's frozen, we're identifying which stocks have real support
→ While the news screams "crash," we're positioning for the bounce

This is where momentum research matters most.

Anyone can find stocks going up in a bull market. The real edge is knowing:

That's what this week's watchlist is about.

We just dropped a new batch of setups inside Crown Elite — and you're invited.

Elite members got this morning:

Our latest Elite alert: $ONDS → Up 80% since SEP 12

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) has skyrocketed +257% over the past month, becoming one of the most explosive movers in the biotech sector. The surge comes as investors pile into next-gen metabolic disease therapies, and Terns’ clinical progress in NASH and obesity has positioned it at the center of one of biotech’s most lucrative emerging markets.

The rally accelerated after strong Phase II data revealed meaningful efficacy signals for TERN-501 — a selective THR-β agonist viewed as a potential competitor in the multibillion-dollar NASH treatment landscape. With analysts highlighting its clean safety profile and its combination therapy potential, momentum around Terns has surged. As excitement builds ahead of upcoming catalysts and partnership opportunities, TERN is rapidly emerging as one of the strongest momentum names in the entire biotech innovation space right now.

1 Month Performance:

Click here to see the chart

Nuvation Bio Inc. (NYSE: NUVB) has surged +59% over the past month as investors rotate into clinical-stage oncology names showing meaningful scientific progress. The company is developing next-generation cancer therapeutics targeting some of the most difficult, treatment-resistant tumors — a space where breakthrough success can unlock massive upside.

Momentum accelerated after Nuvation Bio announced positive early-stage clinical updates for its NUV-868 BET inhibitor program, highlighting encouraging safety and anti-tumor activity signals. With additional data readouts approaching and renewed investor confidence in precision oncology platforms, enthusiasm around NUVB has strengthened sharply. As the company advances its pipeline across multiple solid tumor indications, NUVB is emerging as one of the strongest momentum names in the innovative cancer-drug development sector right now.

1 Month Performance:

Click here to see the chart

Lumentum Holdings Inc. (NASDAQ: LITE) has rallied +62% over the past month as investors pour into optical and laser technology names tied to AI, cloud infrastructure, and next-generation telecom upgrades. The company is a leading supplier of advanced photonics used in data centers, 3D sensing, and high-speed networking — all critical components in the backbone of AI and hyperscale computing.

Momentum accelerated after Lumentum delivered strong preliminary results and signaled improving demand trends across both its cloud and telecom segments. Renewed optimism around AI-driven optical spending, combined with management’s outlook for margin expansion, has fueled significant upside. With hyperscalers upgrading networks and global telecom operators preparing for higher-bandwidth architectures, LITE is emerging as one of the strongest momentum names in the entire photonics and optical-infrastructure sector right now.

1 Month Performance:

Click here to see the chart

10x Genomics, Inc. (NASDAQ: TXG) has climbed +40% over the past month as investors rotate back into high-innovation life sciences names powering the next wave of genomic and cellular research. The company is a global leader in single-cell and spatial biology technologies — tools that are becoming essential for drug discovery, oncology research, and advanced biomedical breakthroughs.

Momentum picked up after renewed demand signals across academic labs, biotech companies, and pharmaceutical partners, paired with optimism around 10x’s new product cycles and upgraded instrument platforms. As funding conditions in biotech stabilize and research activity rebounds, TXG’s cutting-edge hardware and consumables business is benefiting from accelerating adoption. With the company positioned at the forefront of precision biology, TXG is emerging as one of the strongest momentum names in the high-growth genomics tools sector right now.

1 Month Performance:

Click here to see the chart

Globus Medical, Inc. (NYSE: GMED) has surged +47% over the past month as investors flock to high-growth medical device names tied to spine, trauma, and robotic-assisted surgery. The company develops advanced implants, navigation systems, and surgical robots that are increasingly being adopted by hospitals looking to improve outcomes and efficiency in complex spine and orthopedic procedures.

Momentum accelerated as procedure volumes and demand for Globus’ innovative product portfolio continued to strengthen, reinforcing the company’s positioning at the cutting edge of surgical technology. With ongoing rollouts of next-gen robotics platforms, expanding hospital partnerships, and a growing global footprint, GMED is emerging as one of the strongest momentum names in the entire medtech and spine-surgery sector right now.

1 Month Performance:

Click here to see the chart

We send stocks like this all the time inside our Crown Elite Research Service.

You get access to real trade setups before they move with —

Talk soon,

— Jordan

👑 Crown Trading